BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 31662869)

  • 1. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.
    Zhou YJ; Ye FZ; Li YY; Pan XY; Chen YX; Wu XX; Xiong JJ; Liu WY; Xu SH; Chen YP; Zheng MH
    United European Gastroenterol J; 2019 Oct; 7(8):1124-1134. PubMed ID: 31662869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.
    Polyzos SA; Slavakis A; Koumerkeridis G; Katsinelos P; Kountouras J
    Horm Metab Res; 2019 Feb; 51(2):134-140. PubMed ID: 30273934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
    Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
    Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
    Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
    Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.
    Lykiardopoulos B; Hagström H; Fredrikson M; Ignatova S; Stål P; Hultcrantz R; Ekstedt M; Kechagias S
    PLoS One; 2016; 11(12):e0167776. PubMed ID: 27936091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Peleg N; Issachar A; Sneh-Arbib O; Shlomai A
    Dig Liver Dis; 2017 Oct; 49(10):1133-1138. PubMed ID: 28572039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease.
    Cen C; Wang W; Yu S; Tang X; Liu J; Liu Y; Zhou L; Yu J; Zheng S
    Hepatol Int; 2020 Sep; 14(5):808-816. PubMed ID: 32572817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.